Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-progranulin shRNA
- Development stage
- Preclinical
- Lead developer
- Thomas Jefferson University
- Modality
- Viral-delivered RNAi → In Vivo RNAi → Gene Silencing → Gene Therapies, RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intrathecal
01
Overview
Anti-progranulin shRNA is a short hairpin RNA (shRNA) designed to silence the expression of progranulin (PGRN), a growth factor that acts as an autocrine regulator in various cancers, including bladder cancer. By targeting progranulin mRNA for degradation via the RNA interference (RNAi) pathway, this shRNA inhibits tumor cell motility, invasion, and anchorage-independent growth. Research conducted at Thomas Jefferson University and other institutions has demonstrated that progranulin depletion using this shRNA significantly reduces in vivo tumor formation in xenograft and orthotopic bladder cancer models and increases the sensitivity of cancer cells to cisplatin.
- Other names
- progranulin-targeting shRNAshRNA targeting progranulin
02
Targets
GRN (Progranulin)
Beyond the preview
Go deeper on anti-progranulin shRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-progranulin shRNA.